Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 2 |
| Introduction | 8 | 9 |
| Drugs and Biologics Inspections and Warning Letters | 8 | 1 |
| Public Health Service Act and Biologics | 9 | 1 |
| Drug Recall Process | 9 | 2 |
| Drug Recalls Reported by CDER | 11 | 2 |
| Drug Recalls Reported by CBER | 13 | 3 |
| GBI Research Report Guidance | 16 | 1 |
| Regulatory Intelligence on Biologics Recalls: Overview | 17 | 9 |
| Overview of Biologics | 17 | 1 |
| Overview of Biologics Manufacturing Process | 18 | 1 |
| Biologics Recalls | 19 | 1 |
| Reasons for Recalls | 19 | 1 |
| Risk Management for Drugs and Biologics | 20 | 1 |
| Labeling Revisions on ESAs Following FDA Recommendation and CMS Changes to Reimbursement | 20 | 1 |
| Updated Labeling of Tysabri to Warn Against Increased Risk of Progressive Multifocal Leukoencephalopathy (PML) | 21 | 1 |
| Regulatory Responsibilities and Procedures Involving Recalls | 21 | 1 |
| Reasons for Manufacturers to Initiate Recalls | 21 | 1 |
| FDA Responsibilities and Procedures Outline | 22 | 1 |
| Responsibilities of the Agencies Involved | 22 | 1 |
| Case Study 1 - Octagam 5% Returned to Market after Resolution of Manufacturing Issues by Octapharma | 23 | 1 |
| Octagam 5% Recalled from Markets Due to Increase of Thromboembolic Events (TEEs) | 23 | 1 |
| Changes to the Manufacturing Process | 23 | 1 |
| Favorable Opinion of Regulatory Authorities and Approval of the Product | 23 | 1 |
| Case Study 2 - Heparin Crisis a Reflection of FDA Failure | 24 | 1 |
| Heparin Contamination Forced Several Companies to Recall Products | 24 | 1 |
| Source of Contamination was in China | 24 | 1 |
| Regulatory Failure Led to Contaminated Heparin Distribution | 24 | 1 |
| Case Study 3 - Shortened Expiration Period for 2009 H1N1 Vaccine in Pre-filled Syringes by Sanofi Pasteur | 25 | 1 |
| Five Lots with Lower than Pre-Specified Potency Levels Recalled from the Market | 25 | 1 |
| Change of Expiration Date for the Remaining Lots as a Protective Measure | 25 | 1 |
| Regulatory Intelligence on Biologics Recalls Trends Analysis | 26 | 44 |
| Analysis of Biologics Recalls 2004 2010 | 26 | 6 |
| Reasons for Biologics Recalls | 32 | 1 |
| Biologics Recalls by Therapy Area | 33 | 2 |
| Biologics Recalls by Drug Class | 35 | 2 |
| Biologics Recalls by Different Dosage Forms | 37 | 2 |
| Biologics Recalls by Companies | 39 | 4 |
| Analysis of Biologics Recalls 2007 2010 | 43 | 1 |
| Reasons for Biologics Recalls | 43 | 1 |
| Biologics Recalls by Therapy Area | 44 | 1 |
| Biologics Recalls by Drug Class | 45 | 1 |
| Biologics Recalls by Dosage Form | 46 | 1 |
| Biologics Recalls by Companies | 47 | 2 |
| Analysis of Biologics Recalls 2007 | 49 | 1 |
| Reasons for Biologics Recalls, 2007 | 49 | 1 |
| Biologics Recalls by Therapy Area, 2007 | 50 | 1 |
| Biologics Recalls by Drug Class, 2007 | 51 | 1 |
| Biologics Recalls by Dosage Form, 2007 | 52 | 1 |
| Biologics Recalls by Companies, 2007 | 53 | 2 |
| Analysis of Biologics Recalls 2008 | 55 | 1 |
| Reasons for Biologics Recalls, 2008 | 55 | 2 |
| Biologics Recalls by Therapy Area, 2008 | 57 | 1 |
| Biologics Recalls by Drug Class, 2008 | 58 | 1 |
| Biologics Recalls by Dosage Form, 2008 | 59 | 1 |
| Biologics Recalls by Companies, 2008 | 60 | 1 |
| Analysis of Biologics Recalls 2009 | 61 | 1 |
| Reasons for Biologics Recalls, 2009 | 61 | 1 |
| Biologics Recalls by Therapy Area, 2009 | 62 | 1 |
| Biologics Recalls by Drug Class, 2009 | 62 | 1 |
| Biologics Recalls by Dosage Form, 2009 | 62 | 1 |
| Biologics Recalls by Companies, 2009 | 63 | 1 |
| Analysis of Biologics Recalls 2010 | 64 | 1 |
| Reasons for Biologics Recalls, 2010 | 64 | 2 |
| Biologics Recalls by Therapy Area, 2010 | 66 | 1 |
| Biologics Recalls by Drug Class, 2010 | 67 | 1 |
| Biologics Recalls by Dosage Form, 2010 | 68 | 1 |
| Biologics Recalls by Companies, 2010 | 69 | 1 |
| Regulatory Intelligence on Drug Recalls - Appendix | 70 | 3 |
| Market Definitions | 70 | 1 |
| Abbreviations | 70 | 1 |
| Research Methodology | 71 | 1 |
| Coverage | 71 | 1 |
| Regulatory Intelligence on Biologics Recalls Overview | 71 | 1 |
| Regulatory Intelligence on Biologics Recalls Trend Analysis | 71 | 1 |
| Contact Us | 72 | 1 |
| Disclaimer | 72 | 1 |
| Sources | 72 | 1 |